LBA3 Enzalutamide in men with chemotherapy-naive metastatic castration resistant prostate cancer (MCRPC): Primary and European regional results of the phase 3 prevail study

B Tombal; P Iversen; K Miller; T Tammela; Michael Borre; A Bjartell; P Mulders; J Kliment; J Ramon; V Matveev

LBA3 Enzalutamide in men with chemotherapy-naive metastatic castration resistant prostate cancer (MCRPC): Primary and European regional results of the phase 3 prevail study

B Tombal, P Iversen, K Miller, T Tammela, Michael Borre, A Bjartell, P Mulders, J Kliment, J Ramon, V Matveev

Original language	English
Journal	European Urology Supplements
Volume	13
Issue number	1
Pages (from-to)	LBA3
ISSN	1569-9056
Publication status	Published - 2014

Cite this

@article{bdf0986972854fe69fffc747d4b271fe,

title = "LBA3 Enzalutamide in men with chemotherapy-naive metastatic castration resistant prostate cancer (MCRPC): Primary and European regional results of the phase 3 prevail study",

author = "B Tombal and P Iversen and K Miller and T Tammela and Michael Borre and A Bjartell and P Mulders and J Kliment and J Ramon and V Matveev",

year = "2014",

language = "English",

volume = "13",

pages = "LBA3",

journal = "European Urology, Supplements",

issn = "1569-9056",

publisher = "Elsevier BV",

number = "1",

}

TY - ABST

T1 - LBA3 Enzalutamide in men with chemotherapy-naive metastatic castration resistant prostate cancer (MCRPC): Primary and European regional results of the phase 3 prevail study

AU - Tombal, B

AU - Iversen, P

AU - Miller, K

AU - Tammela, T

AU - Borre, Michael

AU - Bjartell, A

AU - Mulders, P

AU - Kliment, J

AU - Ramon, J

AU - Matveev, V

PY - 2014

Y1 - 2014

M3 - Conference abstract in journal

VL - 13

SP - LBA3

JO - European Urology, Supplements

JF - European Urology, Supplements

SN - 1569-9056

IS - 1

ER -